Search

Displaying results 9311 - 9320 of 10000 in total
  1. Drug

    Naphthoquine

    go.drugbank.com/drugs/DB16249
    Investigational

    Naphthoquine is under investigation in clinical trial NCT01930331 (Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO).

  2. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  3. Drug

    Cytochrome C

    go.drugbank.com/drugs/DB18543
    Investigational

    Cytochrome C is a hemeprotein that plays a role in the mitochondrial electron-transport chain.

  4. Drug

    RGG0853

    go.drugbank.com/drugs/DB18669
    Experimental

    RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.

  5. Drug

    Pimasertib

    go.drugbank.com/drugs/DB14904
    Investigational

    Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).

    Synonyms: N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
  6. Drug

    Methopterin

    go.drugbank.com/drugs/DB16620
    Investigational

    Methopterin is thought to have effects on osteoclasts and to inhibit inflammatory bone destruction.[A229843]

  7. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically ...

  8. Drug

    Flovagatran

    go.drugbank.com/drugs/DB05714
    Experimental

  9. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be...

  10. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.